Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Advises Credit Suisse on $1.6B WuXi PharmaTech Deal

April 26, 2010

NEW YORK, April 26, 2010 — Charles River Laboratories International, Inc., a global provider of research models and associated services and of preclinical drug development services, and WuXi PharmaTech (Cayman) Inc., a drug research and development outsourcing company with expertise in discovery chemistry and with operations in China and the United States, today announced the signing of a definitive agreement under which Charles River and WuXi will combine in a cash and stock transaction valued at approximately $1.6 billion. Covington & Burling LLP advised Credit Suisse, financial advisor to WuXi, on the deal.

Credit Suisse, headquartered in Zurich, is a financial services company that operates in more than 50 countries worldwide.

The New York-based Covington corporate team was led by partner Jack S. Bodner, with associate Mary J. Grendell.

Share this article: